Polyunsaturated Fatty Acids And Lipid Mediators Controlling Chronic Inflammation In Asthma

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
O. Kytikova, Y. Denisenko, T. Novgorodtseva, I. S. Kovalenko, M. Antonyuk
{"title":"Polyunsaturated Fatty Acids And Lipid Mediators Controlling Chronic Inflammation In Asthma","authors":"O. Kytikova, Y. Denisenko, T. Novgorodtseva, I. S. Kovalenko, M. Antonyuk","doi":"10.15275/rusomj.2023.0201","DOIUrl":null,"url":null,"abstract":"Asthma is a common chronic heterogeneous inflammatory respiratory disease with complex pathogenesis. Chronic lung inflammation can be the result of a defect in the resolution of the inflammatory process caused by an imbalance between the synthesis of proinflammatory and pro-resolving lipid mediators. The identification of immunomodulatory effects of eicosanoids, specialized pro-resolving mediators (SPMs), and endocannabinoids synthesized from polyunsaturated fatty acids (PUFAs) allows taking a fresh look at the ways of controlling inflammation rather than solely at its mechanisms. The use of ω-3 PUFA-containing food supplements in combination with standard therapy leads to improved asthma control due to the ability of ω-3 PUFAs to stimulate SPM synthesis and inhibit intracellular signaling pathways of inflammation. Lipid mediators are agonists of peroxisome proliferator-activated receptors (PPARs) and glucocorticoid receptors (GR) that have anti-inflammatory properties. The receptors that are widely expressed in the pulmonary epithelium, endothelium, dendritic cells, eosinophils, fibroblasts, and macrophages play an important role in the regulation of immunometabolic homeostasis in the bronchopulmonary system. Our review systematizes the published data on the properties and mechanism of action of biologically active ω-3 and ω-6 PUFAs involved in the inflammatory process in asthma. Also, this article presents the prospects of using ω-3 PUFAs for the resolution of inflammation in asthma.","PeriodicalId":21426,"journal":{"name":"Russian Open Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Open Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15275/rusomj.2023.0201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Asthma is a common chronic heterogeneous inflammatory respiratory disease with complex pathogenesis. Chronic lung inflammation can be the result of a defect in the resolution of the inflammatory process caused by an imbalance between the synthesis of proinflammatory and pro-resolving lipid mediators. The identification of immunomodulatory effects of eicosanoids, specialized pro-resolving mediators (SPMs), and endocannabinoids synthesized from polyunsaturated fatty acids (PUFAs) allows taking a fresh look at the ways of controlling inflammation rather than solely at its mechanisms. The use of ω-3 PUFA-containing food supplements in combination with standard therapy leads to improved asthma control due to the ability of ω-3 PUFAs to stimulate SPM synthesis and inhibit intracellular signaling pathways of inflammation. Lipid mediators are agonists of peroxisome proliferator-activated receptors (PPARs) and glucocorticoid receptors (GR) that have anti-inflammatory properties. The receptors that are widely expressed in the pulmonary epithelium, endothelium, dendritic cells, eosinophils, fibroblasts, and macrophages play an important role in the regulation of immunometabolic homeostasis in the bronchopulmonary system. Our review systematizes the published data on the properties and mechanism of action of biologically active ω-3 and ω-6 PUFAs involved in the inflammatory process in asthma. Also, this article presents the prospects of using ω-3 PUFAs for the resolution of inflammation in asthma.
控制哮喘慢性炎症的多不饱和脂肪酸和脂质介质
哮喘是一种常见的慢性异质性炎症性呼吸道疾病,发病机制复杂。慢性肺部炎症可能是由促炎和促分解脂质介质合成失衡引起的炎症过程分解缺陷的结果。二十碳烷类、专门的促分解介质(SPMs)和由多不饱和脂肪酸(PUFA)合成的内源性大麻素的免疫调节作用的鉴定,使我们能够重新审视控制炎症的方法,而不仅仅是其机制。由于ω-3 PUFA具有刺激SPM合成和抑制炎症细胞内信号通路的能力,将含有ω-3 PUFAs的食品补充剂与标准治疗相结合使用可改善哮喘控制。脂质介质是过氧化物酶体增殖物激活受体(PPARs)和糖皮质激素受体(GR)的激动剂,具有抗炎特性。广泛表达于肺上皮、内皮、树突状细胞、嗜酸性粒细胞、成纤维细胞和巨噬细胞中的受体在调节支气管肺系统的免疫代谢稳态中发挥着重要作用。我们的综述系统化了已发表的关于参与哮喘炎症过程的生物活性ω-3和ω-6 PUFA的性质和作用机制的数据。此外,本文还介绍了使用ω-3 PUFA解决哮喘炎症的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Russian Open Medical Journal
Russian Open Medical Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
0.90
自引率
0.00%
发文量
39
期刊介绍: Russian Open Medical Journal (RusOMJ) (ISSN 2304-3415) is an international peer reviewed open access e-journal. The website is updated quarterly with the RusOMJ’s latest original research, clinical studies, case reports, reviews, news, and comment articles. This Journal devoted to all field of medicine. All the RusOMJ’s articles are published in full on www.romj.org with open access and no limits on word counts. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. The RusOMJ team is based mainly in Saratov (Russia), although we also have editors elsewhere in Russian and in other countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信